Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Holcus lanatus pollen extract is an allergenic extract derived from the pollen of the Holcus lanatus plant, which is also known as Yorkshire Fog or velvet grass. Developed and marketed by ALK-Abelló, Inc., it is classified as a non-standardized, biological product. This extract is utilized for both diagnostic and therapeutic purposes. For diagnosis, it is administered via percutaneous or intradermal skin tests to identify sensitivity to velvetgrass pollen. Therapeutically, it is used in allergen immunotherapy (hyposensitization) to treat allergic rhinitis and rhino-conjunctivitis. This treatment involves administering gradually increasing doses of the allergen to desensitize the immune system, thereby building tolerance and reducing allergic symptoms. The extract is formulated as an injection solution and has been on the market since 1965.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Holcus lanatus pollen extract.